Upper Respiratory Tract Disorders is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Upper Respiratory Tract Disorders have a 76.92% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Upper Respiratory Tract Disorders compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Upper Respiratory Tract Disorders overview
Upper respiratory infection (URI) is a common acute illness that affects the nasal passages and throat. Symptoms include cough, excess mucus. Some types of URIs include rhinitis, pharyngitis, tonsillitis, laryngitis, common cold, sinusitis, epiglottitis, laryngotracheitis. They are most commonly caused by viruses sometimes bacteria as well. First-line treatment is penicillin. Erythromycin can be used in patients who are allergic to penicillin. Amoxicillin, azithromycin (Zithromax), and first-generation cephalosporins are appropriate alternatives.
For a complete picture of PTSR and LoA scores for drugs in Upper Respiratory Tract Disorders, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.